叶飞

博士，教授，博士生导师、硕士生导师

办 公 室： 6#224

电子邮件：yefei@zstu.edu.cn; yefeizju@126.com

研究方向：计算机辅助药物设计；药物化员工物学；

叶飞教授运用计算生物学和药物分子设计等理论模拟方法，结合化学和生物学实验验证平台，开展理论模拟驱动的创新药物研发、靶标动力学行为研究和药物作用机制研究。获中国科学院经理优秀奖，入选浙江省高层次特殊人才支持计划、首批“浙江省高校领军人才培养计划”青年优秀人才、太阳成集团tyc151cc “青年拔尖人才培养计划”等人才项目，任《Frontiers in Chemistry》Topic主编，APSB、JMC等期刊审稿人。在科研方面，近年来主持国家基金2项，省部级项目3项，横向课题多项，作为项目骨干参与重点研发计划“生物与信息融合（BT与IT融合）”重点专项等。以第一或通讯作者身份（含共同）在Nature、Nature Communications、JACS、Angew、JMC等著名杂志共发表SCI论文30余篇，授权发明专利6项；在教学方面，指导本科生获全国老员工生命科学创新创业大赛一等奖、全国老员工生命科学竞赛三等奖、浙江省生命科学竞赛二等奖、浙江省老员工科技创新活动计划（新苗人才计划）资助等。指导硕士研究生20余名，其中多人赴法国巴黎笛卡尔大学、华东师范大学等继续深造，2人获校优秀硕士论文。

主要学习工作经历

2008.9~2013.7 中国科学院上海药物研究所，药物发现与设计中心（新药研究国家重点实验室），药物设计学，硕博连读

导师：蒋华良/罗成 研究员

2004.9~2008.7     浙江大学，药学院，药学，本科

2013.7~至今       太阳成集团tyc151cc，太阳成集团tyc151cc，讲师/副教授/教授

2019.3~2020.7     加州大学旧金山分校（UCSF），访问学者

导师：Matt Jaconson教授

2018.3~2018.6     亚利桑那州立大学，访问学者

导师：Xiaojun Tian教授

主要学术及社会兼职

Frontiers in Chemistry杂志Topic主编

中国药学会智能药物青年专委会委员

钱塘区欧美同学会，理事

民盟浙江省委会青年委员会，委员

获奖与荣誉

2022年，入选浙江省高层次人才特殊支持计划青年拔尖人才；

2021年，入选太阳成集团tyc151cc第二批“青年拔尖人才培养计划”杰出青年教师培养计划；

2020年，入选首批“浙江省高校领军人才培养计划”青年优秀人才；

2018年，入选太阳成集团tyc151cc首批“青年拔尖人才培养计划”优秀青年教师培养计划；

2013年，获中国科学院经理优秀奖；

2008年，获浙江大学优秀毕业生；

主持主要科研项目

1. 国家自然科学基金面上项目，82373729，新型PRMT1选择性抑制剂的设计、合成及抗实体瘤活性研究，2024.1-2027.12，49万元，主持

2. 国家自然科学基金青年科学基金项目，81402849，靶向menin-MLL相互作用界面的药物发现与药物设计，2015.1-2017.12，23万元，主持；

3. 浙江省高层次人才特殊支持计划青年拔尖人才，2023.6-2026.6，80万元，主持；

4. 浙江省自然科学基金面上基金项目，LY18H300008，针对蛋白质精氨酸甲基转移酶PRMT1的药物发现与化学干预研究，2018.1-2020.12，10万元，主持；

5. 浙江省科技计划公益类项目，2015C33159，基于金黄色葡萄球菌ClpP的抗菌药物发现与药物设计，2015.4-2017.6，15万元，主持；

6. 浙江省自然科学基金青年科学基金项目，LQ14H300003，基于DNA甲基转移酶DNMT1的抗肿瘤药物发现与药物设计，2014.1-2016.12，5万元，主持；

7. 临港实验室“求索杰出青年计划”开放课题，基于全新作用机制的DNA甲基化抑制剂发现和抗实体瘤研究，LG-QS-202205-07，2022.1-2024.12，300万元，参与（项目参与单位负责人，主持经费51万）；

8. 新药研究国家重点实验室开放课题，SIMM1403KF-06，靶向Menin-MLL 相互作用的药物设计与药物发现，2014.4-2015.5，8万元，主持；

9. 横向课题，浙江大学，PRMT1小分子抑制剂应用于抗肿瘤治疗的药物研发和产业化，2022.9-2025.9，30万元，主持；

    

   通讯或第一作者的代表性论文（*代表通讯作者）：

1. Youyi Zhang¹, Fei Ye¹, Tongtong Zhang, Shiyun Lv, Liping Zhou, He Lin, Fei Guo, Cheng Luo*, Shujia Zhu*. Structural basis of ketamine action on human NMDA receptors. Nature, 596:301–305, 2021. (IF = 69.504)

2. Yuzhou Huang, Yiran Wang, Chang Cai, Lin Zhang*, Fei Ye*, Liang Zhang*.The β-Ketoacyl-ACP Synthase FabF Catalyzes Carbon-Carbon Bond Formation in a Bimodal Pattern for Fatty Acid Biosynthesis. Angew Chem Int Ed, 63:e202407921, 2024. (IF = 16.1)

3. Xiaotong Diao¹, Fei Ye¹, Meina Zhang, Xintong Ren, Xiaoxu Tian, Jingping Lu, Xiangnan Sun, Zeng Hou, Xiaoyu Chen, Fengwei Li, Jingjing Zhuang, Hong Ding, Chao Peng, Fraydoon Rastinejad*, Cheng Luo*, Dalei Wu*. Identification of oleoylethanolamide as an endogenous ligand for HIF-3α. Nature Communications, 13:2529, 2022. (IF = 17.694)

4. Fei Ye, Jing Huang, HongboWang, Cheng Luo*, Kehao Zhao*.Targeting epigenetic machinery: Emerging novel allosteric inhibitors. Pharmacology & Therapeutics, 204:107406, 2019. (IF = 13.400)

5. Baoen Chen¹, Fei Ye¹, Lu Yu¹, Guifang Jia, Xiaotian Huang, Xueju Zhang, Shuying Peng, Kai Chen, Meining Wang, Shouze Gong, Ruihan Zhang, Jinya Yin, Haiyan Li, Yiming Yang, Hong Liu, Jiwen Zhang, Haiyan Zhang, Ao Zhang, Hualiang Jiang, Cheng Luo*, and Cai-Guang Yang*. Development of Cell-active N⁶-Methyladenosine RNA Demethylase FTO Inhibitor. Journal of the American Chemical Society, 134(43): 17963–17971, 2012. (IF = 16.383)

6. Zhihao Liu, Min Lin, Chenyu Liu,  Xin Chen, Qian Chen, Xinyu Li, Xiaoyan Wu, Yahui Wang, Lei Wang, Fan Yang, Cheng Luo, Jia Jin,* and Fei Ye*. Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma. Journal of Medicinal Chemistry, 67(8):6313-6326, 2024. (IF = 8.039)

7. Chen Wang, Hao Jiang, Jia Jin, Yiqian Xie, Zhifeng Chen, Hao Zhang, Fulin Lian, Yu-Chih Liu, Chenhua Zhang, Hong Ding, Shijie Chen, Naixia Zhang, Yuanyuan Zhang, Hualiang Jiang, Kaixian Chen, Fei Ye*, Zhiyi Yao* and Cheng Luo*. Development of Potent Type I Protein Arginine Methyltransferase (PRMT) Inhibitors of Leukemia Cell Proliferation. Journal of Medicinal Chemistry, 60 (21): 8888–8905, 2017. (IF = 8.039)

8. Linghao Hu, Huiyun Li, Junlin Qin, Dan Yang, Jieming Liu, Xiaomin Luo, Jingkun Ma, Cheng Luo, Fei Ye*, Yubo Zhou*, Jia Li*, Mingliang Wang*. Discovery of PVD-06 as a Subtype-Selective and Efficient PTPN2 Degrader. Journal of Medicinal Chemistry, 66(22):15269-15287, 2023. (IF = 8.039)

9. Amr Abbas, Fei Ye*.Computational methods and key considerations for in silico design of proteolysis targeting chimera (PROTACs). International Journal Of Biological Macromolecules, 277:134293, 2024. (IF = 7.7)

10. Xiao Li¹, Fei Li¹, Fei Ye¹, Haotian Guo4, Wentao Chen, Jia Jin, Yiran Wang, Pengfei Dai, Huili Shi, Hongru Tao, Wenzhen Dang, Yiluan Ding, Mingchen Wang, Hualiang Jiang, Kaixian Chen, Naixia Zhang, Dong Gao*, Yuanyuan Zhang*, Cheng Luo*. Spermine is a natural suppressor of AR signaling in castration-resistant prostate cancer. Cell Reports, 42(7):112798, 2023. (IF = 8.800)

11. Zhen Wang¹, Fengying Fan¹, Zhihai Li¹, Fei Ye¹, Qingxia Wang, Rongchao Gao, Jiaxuan Qiu, Yixin Lv, Min Lin, Wenwen Xu, Cheng Luo*, Xuekui Yu*.Structural insights into the functional mechanism of the ubiquitin ligase E6AP. Nature Communications,15(1):3531, 2024.

12. Chenyu Liu, Yang Li, Zhihao Liu, Chenxi Cao, Min Lin, Xin Chen, Mengting Yuan, Yaohua Fan, Xiaodong Gu, Lei Wang, Fan Yang, Fei Ye*, Jia Jin*.Structure-based discovery of potent CARM1 inhibitors for colorectal cancer therapy. Eur J Med Chem. 269:116288, 2024.

13. Jing Xu, Yiran Wang, Jiali Zhang, Amr Abbas Abdelmoneim, Zhongjie Liang, Lei Wang, Jia Jin, Qi Dai, Fei Ye*. Elastic network models and molecular dynamic simulations reveal the molecular basis of allosteric regulation in ubiquitin-specific protease 7 (USP7). Computers in Biology and Medicine, 162:107068, 2023. (IF = 7.700)

14. Xiao Li, Lun Zhang, Jing Xu, Chenyu Liu, Xiaojian Zhang, Amr Abbas Abdelmoneim, Qian Zhang, Jiaqi Ke, Yingnan Zhang, Lei Wang, Fan Yang, Cheng Luo, Jia Jin*, Fei Ye*. Identification, Synthesis and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases. Journal of Chemical Information and Modeling, 2022, 62(3):692-702. (IF = 6.162)

15. Fei Ye*, Weiyao Zhang, Xiaoqing Ye, Jia Jin, Zhengbing Lv, Cheng Luo*. Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5) through Structure-Based Virtual Screening and Biological Assays. Journal of Chemical Information and Modeling, 58(5):1066-1073, 2018. (IF = 6.162)

16. Zhongjie Liang, Yu Zhu, Jie Long, Fei Ye*, Guang Hu*. Both Intra and Inter-domain Interactions Define the Intrinsic Dynamics and Allosteric Mechanism in DNMT1s. Computational and Structural Biotechnology Journal, 18:749-764, 2020. (IF = 6.155)

17. Fei Ye*, Min Lin, Jia Jin, Sylvain Broussy*. Editorial: Computer-aided drug design: Drug discovery, computational modelling, and artificial intelligence. Frontiers in Chemistry, 18;10:968687, 2022. (IF = 5.545)

18. Fei Ye, Xiangqian Kong, Hao Zhang, Yan Liu, Zhiyuan Shao, Jia Jin, Yi Cai, Rukang Zhang, Linjuan Li, Yang W. Zhang, Yu-Chih Liu, Chenhua Zhang, Wenbing Xie, Kunqian Yu, Hong Ding, Kehao Zhao, Shijie Chen*, Hualiang Jiang, Stephen B. Baylin* and Cheng Luo*. Biochemical Studies and Molecular Dynamic Simulations Reveal the Molecular Basis of Conformational Changes in DNA Methyltransferase-1. ACS Chemical Biology, 13(3):772-781, 2018. (IF = 4.634)

19. Tengfeng Ni¹, Fei Ye¹, Xing Liu, Jie Zhang, Hongchuan Liu, Jiahui Li, Yingyi Zhang, Yingqiang Sun, Meining Wang, Cheng Luo, Hualiang Jiang, Lefu Lan, Jianhua Gan, Ao Zhang, Hu Zhou, and Cai-Guang Yang. Characterization of Gain-of-Function Mutant Provides New Insights into ClpP Structure. ACS Chemical Biology, 11(7):1964-72, 2016. (IF = 4.634)

20. Fei Ye¹, Jie Zhang¹, Hongchuan Liu, Rolf Hilgenfeld, Ruihan Zhang, Xiangqian Kong, Lianchun Li, Junyan Lu, Xinlei Zhang, Donghai Li, Hualiang Jiang*, Cai-Guang Yang*, and Cheng Luo*. Helix unfolding/refolding characterizes the functional dynamics of Staphylococcus aureus CLP protease. Journal of Biological Chemistry, 288(24):17643-17653, 2013. (IF = 5.486)